SCHEMBL17850741

SCHEMBL17850741

O=C(O)c1cnc(Cl)c(OCC2CCOCC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 2/20 0.56
▸ DPP4 P27487 1/20 0.46
▸ PREP P48147 1/20 0.46
▸ FAP Q12884 1/20 0.46
▸ DPP8 Q6V1X1 1/20 0.46
▸ DPP9 Q86TI2 1/20 0.46
▸ PTGER1 P34995 1/20 0.46
▸ SCN9A Q15858 1/20 0.43
▸ MAP4K4 O95819 1/20 0.42
▸ NOX1 Q9Y5S8 1/20 0.41
▸ KMO O15229 2/20 0.41
▸ KDM5A P29375 2/20 0.40
▸ KDM2B Q8NHM5 2/20 0.40
▸ KDM4C Q9H3R0 2/20 0.40
▸ KDM5B Q9UGL1 2/20 0.40
▸ KDM4A O75164 1/20 0.40
▸ GRM4 Q14833 6/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ RXRA P19793 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17835489 0.77 KDM4C (0.43) XDHPTGER1SCN9AKDM5AKDM4C
SCHEMBL840900 0.75 XDH (0.54) XDHMAP4K4
SCHEMBL21314319 0.74 ATXN2 (0.57) XDHPTGER1IRAK4
SCHEMBL17835490 0.74 XDH (0.48) XDHPTGER1SCN9AKMOKDM4C
SCHEMBL30537234 0.74 XDH (0.50) XDHPTGER1KDM5AKDM2BKDM4C
SCHEMBL20502377 0.74 XDH (0.50) XDHPTGER1KDM5AKDM2BKDM4C
SCHEMBL2714328 0.73 TSHR (0.51) DPP4PREPFAPDPP8DPP9
SCHEMBL22262501 0.73 XDH (0.49) XDHPTGER1SCN9AMAP4K4KDM4C
SCHEMBL20476485 0.71 ALDH1A1 (0.50) XDHPTGER1BRD4
SCHEMBL15351916 0.71 DPP4 (0.50) XDHDPP4SCN9AMAP4K4KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 — — US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 — — US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 — — US disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 — — WO disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB XDH 9/4885DPP4 1395/4885PREP 779/4885
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB XDH 9/4885DPP4 1395/4885PREP 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback